CRISPR Gene Therapy Cures Inherited Blood Disorder in Clinical Trial

A landmark clinical trial has demonstrated that CRISPR gene editing can cure sickle cell disease, offering hope to millions worldwide. ## The Treatment Scientists used CRISPR to edit patients' own stem cells, correcting the genetic mutation that causes sickle cell disease. The modified cells were then reinfused into patients. ## Results All 45 trial participants have been effectively cured, with no serious adverse effects after three years of follow-up. Patients no longer experience the painful crises characteristic of the disease. ## Broader Implications This success proves that CRISPR can safely cure genetic diseases in humans, opening the door to treatments for thousands of other genetic conditions. ## Access Challenges The treatment currently costs over $2 million per patient. Researchers and policymakers are working to make it accessible to those who need it most.